Allergy

Blepharitis

COVID-19

Cataract

Comanagement

Comprehensive Eye Exams

Conjunctivitis

Contact Lenses

Cornea

Diabetic Eye Disease

Dry Eye

Geographic Atrophy

Glasses

Glaucoma

LASIK

Lens Technology

Lid and Lash

Myopia

Nutrition

Ocular Surface Disease

Optic Relief

Patient Care

Pediatrics

Presbyopia

Ptosis

Refractive Surgery

Retina

Technology

Therapeutic Cataract & Refractive

News

All News

Practice Management

Media

All Videos

Expert Interviews

Podcasts

Medical World News

Viewpoints

Insights

Case Based Roundtable Series

Case Studies

Case of the Quarter

Practice Ownership

Rapid Readout

What’s Your WhEYE?

Conferences

Conference Coverage

Conference Listing

Conference Recaps

Blog

Publications

Digital Edition

Supplements And Featured Publications

iTech

Partners

Resources

Job Board

Subscribe

Articles

Ocular salvage and preservation of vision are essentially dependent on early diagnosis, and several studies have been conducted to identify the factors leading to delayed diagnosis at presentation.

Parental lag time is primary reason for delayed diagnosis and treatment of retinoblastoma 

TearCare is associated with greater health utility over time but also resulted in significant cost savings compared with CsA.

Sight Sciences releases cost-utility analysis comparing TearCare and cyclosporine 0.05% in dry eye

Specialty care is always needed in any field, and myopia control is no exception.

How can myopia be controlled when only a small percentage of doctors attempt to control it?

Videos

With FDA approval of LENZ Therapeutics’ Vizz (LNZ100), optometrists now have a daily, non-invasive treatment option for presbyopia, giving patients more freedom and clinicians greater flexibility in care.

Another drop in the presbyopia bucket: Dr Bloomenstein shares his excitement for the FDA approval of Vizz

Optometry Times delivers clinical news, practice insights, and research updates by optometrists for optometrists to advance care and patient outcomes.

Advertise

About Us

Editorial

Contact Us

Terms & Conditions

Privacy

Do not sell my Information

Optometry Times – Clinical News & Expert Optometrist Insights

Facebook

Instagram

LinkedIn

Spotlight

Clinical

Myopia- Management

1rem

view

American Academy of Optometry

Conference

Shane Foster, OD discusses highlights from his American Academy of Optometry poster presentation on upper eyelid elevation in acquired ptosis patients with once-daily topical Oxymetazoline 0.1%. 

Test

Topical oxymetazoline HCL ophthalmic solution 0.1% (RVL-1201, RVL Pharmaceuticals, Inc.) provides significant improvement in upper eyelid elevation for ptosis patients

Topical oxymetazoline 0.1% and upper lid elevation: An overview with Shane Foster, OD

Topical oxymetazoline 0.1% and upper lid elevation: An overview with Shane Foster, OD

Newsletter